Business your connection to The Boston Globe

Report questions risks of Lily drug

NEW YORK -- Eli Lilly and Co. has downplayed for about 10 years the risks associated with Zyprexa, which treats schizophrenia, The New York Times said on its website yesterday, citing internal documents from the drug maker and e-mail messages of its managers.

The documents, obtained from a lawyer for mentally ill patients, show Lilly executives kept data from doctors about the drug's tendencies to promote obesity and boost blood sugar, the Times said.

Lilly denied there was a connection between the drug and diabetes. The drug maker said the documents had been taken out of context, the newspaper said.

Today (free)
Yesterday (free)
Past 30 days
Last 12 months
 Advanced search / Historic Archives